Volition Reports 95% Detection of Early-Stage Cancers Using CTCF-Protected ctDNA Sequencing
VolitionRx reported 95% detection of early-stage solid cancers in blinded validation of its CTCF-protected ctDNA Capture-Seq liquid biopsy, according to data presented at the ESMO MAP Conference.